Cue biopharma announces publication in nature journal, scientific reports, of immunotherapeutic platforms immuno-stat and neo-stat

Cambridge, mass., sept. 28, 2021 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted t cells directly within the patient's body, announced today the publication of research titled “ peptide-hla-based immunotherapeutics platforms for direct modulation of antigen-specific t cells ” in the peer-reviewed nature journal, scientific reports. the article describes cue biopharma's il-2 based cue-100 series technology platforms, immuno-stat™ (selective targeting and alteration of t cells) and neo-stat™, being leveraged for the development of first-in-class biologics that enable selective activation of cancer-killing immune t cells within the patient's body.
CUE Ratings Summary
CUE Quant Ranking